Cargando…

Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials

BACKGROUND: Many Chinese patent medicines (CPMs) have been authorized by the Chinese State of Food and Drug Administration for the treatment of the common cold. A number of clinical trials have been conducted and published. However, there is no systematic review or meta-analysis on their efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei, Liu, Bo, Wang, Li-qiong, Ren, Jun, Liu, Jian-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129119/
https://www.ncbi.nlm.nih.gov/pubmed/25074623
http://dx.doi.org/10.1186/1472-6882-14-273
_version_ 1782330196974632960
author Chen, Wei
Liu, Bo
Wang, Li-qiong
Ren, Jun
Liu, Jian-ping
author_facet Chen, Wei
Liu, Bo
Wang, Li-qiong
Ren, Jun
Liu, Jian-ping
author_sort Chen, Wei
collection PubMed
description BACKGROUND: Many Chinese patent medicines (CPMs) have been authorized by the Chinese State of Food and Drug Administration for the treatment of the common cold. A number of clinical trials have been conducted and published. However, there is no systematic review or meta-analysis on their efficacy and safety for the common cold to justify their clinical use. METHODS: We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites for published and unpublished randomized clinical trials (RCTs) of CPMs for the common cold till 31 March 2013. Revman 5.2 software was used for data analysis with effect estimate presented as relative risk (RR) and mean difference (MD) with a 95% confidence interval (CI). RESULTS: A total of five RCTs were identified. All of the RCTs were of high risk of bias with flawed study design and poor methodological quality. All RCTs included children aged between 6 months to 14 years. Results of individual trials showed that Shuanghuanglian oral liquid (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing oral liquid (RR 1.43; 95% CI: 1.15 to 1.77) had higher cure rates compared with antivirus drugs. Most of the trials did not report adverse events, and the safety of CPMs was still uncertain. CONCLUSIONS: Some CPMs showed a potential positive effect for the common cold on cure rate. However, due to the poor methodology quality and the defects in the clinical design of the included RCTs, such as the lack of placebo controlled trials, the inappropriate comparison intervention and outcome measurement, the confirmative conclusions on the beneficial effect of CPMs for the common cold could not be drawn.
format Online
Article
Text
id pubmed-4129119
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41291192014-08-13 Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials Chen, Wei Liu, Bo Wang, Li-qiong Ren, Jun Liu, Jian-ping BMC Complement Altern Med Research Article BACKGROUND: Many Chinese patent medicines (CPMs) have been authorized by the Chinese State of Food and Drug Administration for the treatment of the common cold. A number of clinical trials have been conducted and published. However, there is no systematic review or meta-analysis on their efficacy and safety for the common cold to justify their clinical use. METHODS: We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites for published and unpublished randomized clinical trials (RCTs) of CPMs for the common cold till 31 March 2013. Revman 5.2 software was used for data analysis with effect estimate presented as relative risk (RR) and mean difference (MD) with a 95% confidence interval (CI). RESULTS: A total of five RCTs were identified. All of the RCTs were of high risk of bias with flawed study design and poor methodological quality. All RCTs included children aged between 6 months to 14 years. Results of individual trials showed that Shuanghuanglian oral liquid (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing oral liquid (RR 1.43; 95% CI: 1.15 to 1.77) had higher cure rates compared with antivirus drugs. Most of the trials did not report adverse events, and the safety of CPMs was still uncertain. CONCLUSIONS: Some CPMs showed a potential positive effect for the common cold on cure rate. However, due to the poor methodology quality and the defects in the clinical design of the included RCTs, such as the lack of placebo controlled trials, the inappropriate comparison intervention and outcome measurement, the confirmative conclusions on the beneficial effect of CPMs for the common cold could not be drawn. BioMed Central 2014-07-30 /pmc/articles/PMC4129119/ /pubmed/25074623 http://dx.doi.org/10.1186/1472-6882-14-273 Text en © Chen et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Chen, Wei
Liu, Bo
Wang, Li-qiong
Ren, Jun
Liu, Jian-ping
Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials
title Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials
title_full Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials
title_fullStr Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials
title_full_unstemmed Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials
title_short Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials
title_sort chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129119/
https://www.ncbi.nlm.nih.gov/pubmed/25074623
http://dx.doi.org/10.1186/1472-6882-14-273
work_keys_str_mv AT chenwei chinesepatentmedicinesforthetreatmentofthecommoncoldasystematicreviewofrandomizedclinicaltrials
AT liubo chinesepatentmedicinesforthetreatmentofthecommoncoldasystematicreviewofrandomizedclinicaltrials
AT wangliqiong chinesepatentmedicinesforthetreatmentofthecommoncoldasystematicreviewofrandomizedclinicaltrials
AT renjun chinesepatentmedicinesforthetreatmentofthecommoncoldasystematicreviewofrandomizedclinicaltrials
AT liujianping chinesepatentmedicinesforthetreatmentofthecommoncoldasystematicreviewofrandomizedclinicaltrials